Lotus Pharmaceuticals Co (美時化學製藥), one of the nation’s leading specialty generic drug developers, yesterday gave a positive outlook for this year, setting its sights on the US market for opioid use disorder (OUD) treatments.
The company, which is vying to launch a generic version of buprenorphine and naloxone, a leading agonist treatment for opioid dependence, said that toward the second half of this year, a US court is expected to give its ruling on patent lawsuits initiated by UK-based Indivior PLC, which is marketing the original drug as Suboxone.
The plaintiff’s patent claims are not solid and a favorable ruling is expected, Lotus Pharmaceuticals chairman Andrew Lin (林群) told an investors’ conference, adding that the company is prepared to initiate an “at-risk” launch for the generic treatment despite ongoing lawsuits.
In particular, the company is developing a film version of the OUD treatment that is placed under the tongue or inside the cheek, he said.
As the US Food and Drug Administration approved Sublocade, Indivior’s monthly subcutaneous injection OUD treatment, the British company slowed its litigation against companies making generic versions of Suboxone, Lin said.
The company is also expecting to launch a generic version of Budesonide ER, a corticosteroid indicated for patients with mild to moderate ulcerative colitis, in the final quarter of this year, after gaining a non-infringement ruling against Valeant Pharmaceuticals International Inc and Cosmo Pharmaceuticals NV, which are marketing the original drug as Uceris, he said.
The drug is expected to launch after Valeant’s 180-day exclusivity period ends, allowing the company to tap into a US$190 million market in the US, he said.
Meanwhile, the company has overhauled its goodwill and intangible assets portfolio as it continues to book impairment charges in an effort to reduce risks ahead, Lotus Pharmaceutical executive assistant Nadiya Chen (陳萩雅) said.
The amount of the impairment charges has been cut from NT$500 million (US$17.12 million) in 2016 to about NT$140 million last year, Chen said.
The company reaped gains from cross-region commercial synergies with affiliates of US-based Alvogen and its Asia-based affiliates, which helped lower its operating-to-expense ratio to a record 40 percent, it said.
Efforts to refinance debt have also cut annual interest expenses, Chen said.
As the global generic drug market has undergone significant changes since 2016, with many industry giants such as Teva Pharmaceuticals Industries Ltd and Perrigo Co experiencing precipitous declines, the company is to continue its strategy of specializing in the segment of complex, high-barrier and small-volume products that have high average selling prices, Chen said.
PERSISTENT RUMORS: Nvidia’s CEO said the firm is not in talks to sell AI chips to China, but he would welcome a change in US policy barring the activity Nvidia Corp CEO Jensen Huang (黃仁勳) said his company is not in discussions to sell its Blackwell artificial intelligence (AI) chips to Chinese firms, waving off speculation it is trying to engineer a return to the world’s largest semiconductor market. Huang, who arrived in Taiwan yesterday ahead of meetings with longtime partner Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), took the opportunity to clarify recent comments about the US-China AI race. The Nvidia head caused a stir in an interview this week with the Financial Times, in which he was quoted as saying “China will win” the AI race. Huang yesterday said
Japanese technology giant Softbank Group Corp said Tuesday it has sold its stake in Nvidia Corp, raising US$5.8 billion to pour into other investments. It also reported its profit nearly tripled in the first half of this fiscal year from a year earlier. Tokyo-based Softbank said it sold the stake in Silicon Vally-based Nvidia last month, a move that reflects its shift in focus to OpenAI, owner of the artificial intelligence (AI) chatbot ChatGPT. Softbank reported its profit in the April-to-September period soared to about 2.5 trillion yen (about US$13 billion). Its sales for the six month period rose 7.7 percent year-on-year
MORE WEIGHT: The national weighting was raised in one index while holding steady in two others, while several companies rose or fell in prominence MSCI Inc, a global index provider, has raised Taiwan’s weighting in one of its major indices and left the country’s weighting unchanged in two other indices after a regular index review. In a statement released on Thursday, MSCI said it has upgraded Taiwan’s weighting in the MSCI All-Country World Index by 0.02 percentage points to 2.25 percent, while maintaining the weighting in the MSCI Emerging Markets Index, the most closely watched by foreign institutional investors, at 20.46 percent. Additionally, the index provider has left Taiwan’s weighting in the MSCI All-Country Asia ex-Japan Index unchanged at 23.15 percent. The latest index adjustments are to
CRESTING WAVE: Companies are still buying in, but the shivers in the market could be the first signs that the AI wave has peaked and the collapse is upon the world Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday reported a new monthly record of NT$367.47 billion (US$11.85 billion) in consolidated sales for last month thanks to global demand for artificial intelligence (AI) applications. Last month’s figure represented 16.9 percent annual growth, the slowest pace since February last year. On a monthly basis, sales rose 11 percent. Cumulative sales in the first 10 months of the year grew 33.8 percent year-on-year to NT$3.13 trillion, a record for the same period in the company’s history. However, the slowing growth in monthly sales last month highlights uncertainty over the sustainability of the AI boom even as
RSS